Ghost Tree Capital’s Sarepta Therapeutics SRPT Stock Holding History

Ghost Tree Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$15M	Buy	120,000 +65,000	+118%	+$8.99M	4.53%	3
2024 Q2	$8.69M	Sell	55,000 -70,000	-56%	-$8.99M	2.72%	13
2024 Q1	$16.2M	Buy	125,000 +25,000	+25%	+$3.06M	4.48%	3
2023 Q4	$9.64M	Buy	100,000 +60,000	+150%	+$5.76M	3.15%	7
2023 Q3	$4.85M	Sell	40,000 -45,000	-53%	-$5.09M	1.59%	21
2023 Q2	$9.73M	Buy	85,000 +25,000	+42%	+$3.22M	3.21%	11
2023 Q1	$8.27M	Buy	60,000 +5,000	+9%	+$649K	2.44%	13
2022 Q4	$7.13M	Sell	55,000 -55,000	-50%	-$6.37M	3.04%	15
2022 Q3	$12.2M	Sell	110,000 -20,000	-15%	-$2.02M	3.41%	11
2022 Q2	$9.74M	Buy	130,000 +80,000	+160%	+$5.89M	5.08%	5
2022 Q1	$3.91M	Sell	50,000 -50,000	-50%	-$3.83M	0.85%	23
2021 Q4	$9.01M	Buy	+100,000	New	+$8.55M	3.23%	12
2021 Q1	–	Sell	-40,000	Closed	-$6.82M	–	54
2020 Q4	$6.82M	Sell	40,000 -25,000	-38%	-$3.7M	1.52%	24
2020 Q3	$9.13M	Buy	+65,000	New	+$9.88M	2.64%	12
2020 Q1	–	Sell	-65,000	Closed	-$8.39M	–	61
2019 Q4	$8.39M	Sell	65,000 -155,000	-70%	-$15.6M	1.6%	22
2019 Q3	$16.6M	Sell	220,000 -70,000	-24%	-$8.27M	4.22%	5
2019 Q2	$44.1M	Buy	+290,000	New	+$35.2M	9.14%	1
2019 Q1	–	Sell	-70,000	Closed	-$7.64M	–	43
2018 Q4	$7.64M	Sell	70,000 -140,000	-67%	-$17.5M	2.77%	14
2018 Q3	$33.9M	Buy	210,000 +35,000	+20%	+$4.78M	7.21%	2
2018 Q2	$23.1M	Sell	175,000 -60,000	-26%	-$5.66M	6.81%	3
2018 Q1	$17.4M	Buy	+235,000	New	+$15.7M	3.52%	5
2017 Q4	–	Sell	-100,000	Closed	-$4.54M	–	66
2017 Q3	$4.54M	Buy	+100,000	New	+$4M	0.96%	37
2016 Q4	–	Sell	-150,000	Closed	-$6.02M	–	91
2016 Q3	$9.21M	Sell	150,000 -50,000	-25%	-$1.51M	1.49%	24
2016 Q2	$3.81M	Buy	+200,000	New	+$3.7M	1.1%	37
2016 Q1	–	Sell	-100,000	Closed	-$3.86M	–	64
2015 Q4	$3.86M	Buy	100,000 +90,000	+900%	+$2.92M	1.58%	27
2015 Q3	$321K	Buy	+10,000	New	+$339K	0.14%	71

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Ghost Tree Capital's SRPT Position: Q3 2024 in Review

Ghost Tree Capital increased its Sarepta Therapeutics (SRPT) stake by 118% in Q3 2024, buying an estimated $8.99M and bringing the position to 120,000 shares worth $15M. The position accounts for 4.53% of the portfolio, ranked #3.

Ghost Tree Capital first reported a position in SRPT in Q3 2015 and has held it in 26 quarters since. The position peaked at $44.1M in Q2 2019. 457 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

Ghost Tree Capital held 120,000 shares of Sarepta Therapeutics worth $15M as of Q3 2024.
Ghost Tree Capital bought 65,000 Sarepta Therapeutics shares in Q3 2024, an estimated $8.99M.
Sarepta Therapeutics made up 4.53% of Ghost Tree Capital's portfolio in Q3 2024, its #3 holding.
Ghost Tree Capital first reported a position in Sarepta Therapeutics in Q3 2015 and has held it in 26 quarters since.
Ghost Tree Capital's Sarepta Therapeutics position peaked at $44.1M in Q2 2019.
457 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Ghost Tree Capital's 13F filing for Q3 2024, filed 14 Nov 2024.